New
Mexico Register / Volume XXXVII, Issue 22 / November 17, 2026
This is an amendment to 16.19.20 NMAC, Section 65, 66, 67, and 68 effective 11/17/2026.
16.19.20.65 SCHEDULE I:
A. Section 30-31-6 NMSA 1978, schedule I shall consist of the
following drugs and other substances, by whatever name, common or usual name,
chemical name or brand name designated, listed in this section; Opioids,
unless specifically exempt or unless listed in another schedule, any of the
following opioids, including its isomers, esters, ethers, salts and salts of
isomers, esters, and ethers, whenever the existence of such isomers, esters,
ethers, and salts is possible within the specific chemical designation.
(1) Acetylmethadol;
(2) Allylprodine;
(3) Alphacetylmethadol;
(4) Alphameprodine;
(5) Alphamethadol;
(6) Alpha-methyl fentanyl;
(7) Benzethidine;
(8) Betacetylmethadol;
(9) Betameprodine;
(10) Betamethadol;
(11) Betaprodine;
[ (12) Clonitazene;]
[(13)] (12) Desmethyltramadol;
[(14)] (13) Dextromoramide;
[(15)]
(14) Diampromide;
[(16)]
(15) Diethylthiambutene;
[ [(17)] Dimethylthiambutene;]
[(18)]
(16) Difenoxin;
[(19)]
(17) Dimenoxadol;
[(20)] (18) Dimepheptanol;
[(21)] (19) Dimethylthiambutene;
[(22)] (20) Dioxaphetyl Butyrate;
[(23)] (21) Dipipanone;
[(24)] (22) Ethylmethylthiambutene;
[ (25) Etonitazene;]
[(26)] (23) Etoxeridine;
[(27)] (24) Furethidine;
[(28)] (25) Hydroxypethidine;
[ (29) Isotonitazene;]
[(30)] (26) Ketobemidone;
[(31)] (27) Levomoramide;
[(32)] (28) Levophenacylmorphan;
[(33)] (29) Morpheridine;
[(34)] (30) Noracymethadol;
[(35)] (31) Norlevorphanol;
[(36)] (32) Normethadone;
[(37)] (33) Norpipanone;
[(38)] (34) Phenadoxone;
[(39)] (35) Phenampromide;
[(40)] (36) Phenomorphan;
[(41)] (37) Phenoperidine;
[(42)] (38) Piritramide;
[(43)] (39) Proheptazine;
[(44)] (40) Properidine;
[(45)] (41) Propiram;
[(46)] (42) Racemoramide;
[(47)] (43) Tilidine;
[(48)] (44) Trimeperidine
[(49)]
(45) U-48800;
(2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide,
monohydrochloride;
[(50)]
(46) U-49900;
(trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide;
[(51)]
(47) Beta-Hydroxy-3-Methylfentanyl;
[(52)] (48) 3-Methylthiofentanyl;
[(53)] (49) Acetyl-Alpha-Methyl fentanyl
;
[(54)] (50) Alpha-Methylthiofentanyl ;
[(55)]
(51) Beta-hydroxyfentanyl
;
[(56)]
(52) Para-Fluoro[ ]fentanyl;
[(57)] (53) Thiofentanyl;
[(58)]
(54) Acetyl
fentanyl;
[(59)]
(55) Butyryl
fentanyl;
[(60)]
(56) Betahydroxythiofentanyl;
[(61)]
(57) Furanyl fentanyl;
[(62)]
(58) AH-7921; (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
[(63)]
(59) U47700;
(trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide);
[(64)]
(60) MT-45; (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)[(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)];
[(65)]
(61) W-15;
(4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide);
[(66)] (62) W-18;
(1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide);
[(67)] (63) U-50488;
(2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide);
[(68)]
(64) U50488H;
((-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclo-hexyl]benzeneacetamide).
[(69)]
(65) Fentanyl-related
substances, their isomers, esters, ethers, salts, and salts of isomers, esters
and ethers. Fentanyl-related substance
means any substance, unless specifically exempted or unless listed in another
schedule, that is structurally related to fentanyl by one or more of the
following modifications:
(a) replacement
of the phenyl portion of the phenethyl group by any monocycle, whether or not
further substituted in or on the monocycle;
(b) substitution
in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo,
haloalkyl, amino or nitro groups;
(c) substitution
in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether,
hydroxyl, halo, haloalkyl, amino or nitro groups;
(d) replacement
of the aniline ring with any aromatic monocycle whether or not further
substituted in or on the aromatic monocycle; or
(e) replacement
of the N-propionyl group by another acyl group; or
(f) any
combination of the above substances include, but are not limited to, the
following substances: (reserved)
[(70)]
(66) Acryl
Fentanyl;
[ (71) 4F-butyrfentanyl;]
[ (72) 4-methoxybutyrfentanyl;]
[ (73) Fluorobutyrfentanyl;]
[(74)] (67) Fluorofentanyl;
[(75)]
(68) FIBF; (Para
Fluoro[ ]Isobutyryl Fentanyl);
[(76)] (69) Cyclopropyl fentanyl;
[(77)] (70) Thiofuranyl
fentanyl (Thiophene fentanyl);
[(78)] (71) 3-methylfentanyl
(N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidinyl)-N-phenylpropanamide, its
optical and geometric isomers, salts and salts of isomers;
[(79)] (72) crotonyl fentanyl
((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);
[(80)] (73) valeryl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);
[(81)] (74) N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide
(2′-fluoro ortho-fluorofentanyl;
2′-fluoro 2-fluorofentanyl);
[(82)] (75) N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide
(4′-methyl acetyl fentanyl);
[(83)] (76) beta-phenyl fentanyl or
N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (β′-phenyl
fentanyl; beta′-Phenyl fentanyl; 3-phenylpropanoyl fentanyl);
[(84)] (77) beta-methyl fentanyl or
N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide (β-methyl
fentanyl);
(78) beta-Methylacetyl
fentanyl (N-phenyl-N-(1-(2- phenylpropyl)piperidin-4-yl)acetamid
[(85)] (79) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
(ortho-fluorobutyryl fentanyl; 2-fluorobutyryl
fentanyl);
[(86)] (80) (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide
(ortho-methyl acetylfentanyl; 2-methyl acetylfentanyl);
[(87)] (81) 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide
(ortho-methyl methoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl);
[(88)] (82) N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide
(para-methylfentanyl; 4-methylfentanyl);
[(89)]
(83) N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl);
[(90)] (84) N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide
(thiofuranyl fentanyl; 2-thiofuranyl fentanyl;
thiophene fentanyl);
[(91)] (85) Ethyl (1-phenethylpiperidin-4- yl)(phenyl)carbamate (fentanyl carbamate);
[(92)] (86) N-(2-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)acrylamide (ortho-fluoroacryl
fentanyl);
[(93)] (87) N-(2-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)isobutyramide (ortho-fluoroisobutyryl fentanyl);
[(94)]
(88) N-(4-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)furan-2- carboxamide (para-fluoro furanyl fentanyl);
[(95)]
(89) Cyclopentyl
fentanyl;
[(96)]
(90) Isobutyryl
fentanyl;
[(97)]
(91) Para-chloroisobutyryl fentanyl;
[(98)] (92) Para-methoxybutyryl fentanyl
or 4-MeO-BF; N-(4-Methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide;
[(99)] (93) Para-fluorobutyryl fentanyl or
4-FBF; N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide;
[(100)] (94) Ocfentanil;
[(101)] (95) Ortho-Fluorofentanyl;
[(102)] (96) Tetrahydrofuranyl Fentanyl;
[(103)] (97) Methoxyacetyl Fentanyl;
2-Methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;
[(104)] (98) 4-Fluoroisobutyryl Fentanyl;
[ (105) Para-Fluorofentany;l
(106) Butonitazene
(2-(2-(4-butoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);
(107) Etodesnitazene;
etazene (2-(2-(4-ethoxybenzyl)-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);
(108) Metonitazene
(N, N -diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1 H
-benzimidazol-1-yl)ethan-1-amine);
(109) Flunitazene
(N, N -diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1 H
-benzimidazol-1-yl)ethan-1-amine);
(110) Metodesnitazene
(N,6 N -diethyl-2-(2-(4-methoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine);
(111) Protonitazene (N, N -diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 H
-benzimidazol-1-yl)ethan-1-amine);
(112)] (99) Brorphine
(1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2 H-benzo[d]imidazol-2-one);
[(113)] (100) Zipeprol
(1-methoxy-3-[4-(2-methoxy-2- phenylethyl)piperazin-1-yl]-1-
phenylpropan-2-ol).
(101) 2',5'-Dimethoxyfentanyl (N-(1-(2,5- dimethoxyphenethyl)piperidin-4-yl)-Nphenylpropionamide);
(102) 3-Furanyl Fentanyl;
(N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);
(103) Alpha-Methyl Butyryl Fentanyl;
(104) Isovaleryl
Fentanyl; (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
(105) Meta-Fluorofentanyl;
(106) Meta-Fluorofuranyl Fentanyl;
(107) Meta-Fluroisobutyryl Fentanyl;
(108) Ortho-Fluoro Furanyl
Fentanyl; (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(109) Para-Methoxyfuranyl Fentanyl;
(110) Para-Methylcyclopropyl Fentanyl;
(111) 2-Methyl
AP-237: (1-(2-methyl-4-(3-phenylprop-2-en-1- yl)piperazin-1-yl)butan-1-one);
(112) Dihydromorphine; Paramorphan;
(113) Ortho-Chlorofentanyl;
(N-(2-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
(114) Ortho-Methylcyclopropylfentanyl;
(N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
(115) Para-Chlorofentanyl
(N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
(116) Para-Fluoro
valeryl fentanyl;
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide);
(117) Tetrahydrothiophene fentanyl:
(N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrothiophene-2-carboxamide);
(118) Benzimidazole opioids; Nitazenes;
(a) 5-Methyl etodesnitazene[PD42.1];
2-(2-(4-Ethoxybenzyl)-5-methyl-1H-benzimidazol-1-yl)- N,N-diethylethan-1-amine;
(b) Butonitazene
(2-(2-(4-butoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);
(c) Clonitazene;
(d) Ethyleneoxynitazene;
2-(2-((2,3-Dihydrobenzofuran-5-yl)methyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine;
(e) Etodesnitazene; etazene
(2-(2-(4-ethoxybenzyl)-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);
(f) Etonitazene;
(g) Flunitazene (N, N
-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1 H -benzimidazol-1-yl)ethan-1-amine);
(h) Isotonitazene;
(i) Methylenedioxynitazene;
3′,4′¬Methylenedioxynitazene; 2-(2-(Benzodioxol-5-ylmethyl)-5-nitro-1H-benzimidazol-
1-yl)-N,N-diethylethan-1-amine;
(j) Metodesnitazene (N,6 N
-diethyl-2-(2-(4-methoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine);
(k) Metonitazene (N, N
-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1 H -benzimidazol-1-yl)ethan-1-amine);
(l) Metonitazepyne;
2-(4-Methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole
(N-pyrrolidino metonitazene);
(m) N-Desethyl etonitazene;
2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-Nethylethan-1-amine;
(n) N-Desethyl isotonitazene
(N-ethyl-2-(2-(4-isopropoxylbenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amin);
(o) N-Desethyl protonitazene:
N-Ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1Hbenzimidazol-1-yl)ethan-1-amine;
(p) N,N-Dimethylamino etonitazene;
2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)- N,N-dimethylethan-1-amine;
(q) N-Pyrrolidino Etonitazene;
Etonitazepyne;
(r) N-Piperidinyl Etonitazene;
Etonitazepipne;
(s) N-Pyrrolidino isotonitazene;
Isotonitazepyne; 2-(4-Isopropoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-
yl)ethyl)-1H-benzimidazole;
(t) Protonitazene (N, N
-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine);
(u) Protonitazepyne;
5-Nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole
(N-pyrrolidino protonitazene);
B. Opium derivatives: Unless specifically exempt or unless listed in another
schedule, any of the following opium derivatives, its salts, isomers, and salts
of isomers whenever the existence of such salts, isomers and salts of isomers
is possible within the specific chemical designation.
(1) Acetorphine;
(2) Acetyl dihydrocodeine; Acetylcodone;
(3) Benzyl morphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dehydro morphine;
Pseudomorphine;
(9) Etorphine;
(10) Heroin; Diacetylmorphine, diamorphine;
(11) Hydromorphinol;
(12) Methyldesorphine;
(13) Methyldihydromorphine;
(14) Morphine methylbromide;
(15) Morphine methylsulfonate;
(16) Morphine-N-Oxide;
(17) Myrophine;
(18) Nicocodeine;
(19) Nicomorphine;
(20) Normorphine;
(21) Pholcodine;
(22) Thebacon;
(23) Drotebanol;
(24) 6AM; (6-acetylmorphine).
C. Stimulants: Unless specifically exempted or unless listed
in another schedule, any material, compound, mixture or preparation which
contains any quantity of the following substances having a stimulant effect on
the central nervous system, including its salts, isomers, and salts of isomers.
(1) Fenethylline;
(2) NEA; N-ethylamphetamine;
(3) cis-4-methylaminorex; U4Euh;
(4) N, N-dimethylamphetamine;
(5) (BZP), 1-benzylpiperazine;
N-benzylpiperazine;
(6) (DCPP); 2,3-dichlorophenylpiperazine;
(7) (DBZP); dibenzylpiperazine;
(8) (MBZP); methylbenzylpiperazine;
(9) (mCPP);
meta-chlorophenylpiperazine;
(10) (MDBZP); methylenedioxybenzylpiperazine;
(11) (meOPP);
para-methoxyphenylpiperazine;
(12) (pCPP); para-chlorophenylpiperazine;
(13) (pFPP); para-fluorophenylpiperazine;
(14) (2-DPMP), desoxypipradrol;
2-diphenylmethylpiperidine;
(15) D2PM, diphenylprolinol;
diphenyl-2-pyrrolidinemethanol;
(16) HDMP-28; methylnaphthidate;
(17) Nocaine, (+)-CPCA;
3α-carbomethoxy-4β-(4-chlorophenyl)-N-methylpiperidine;
(18) BTQ or butyltolylquinuclidine;
(2-Butyl-3-(p-tolyl)quinuclidine;
(19) Methiopropamine; (N-methyl-1- (thiophen-2-yl)propan-2-amine);
(20) Mesocarb; (N-phenyl-N′ -(3-(1-phenylpropan-2-yl)-1,2,3- oxadiazol-3-ium-5-yl)carbamimidate);
(21) Amineptine (7-
[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5- yl)amino]heptanoic acid);
(22) 4,4′-Dimethylaminorex
(4,4′-DMAR; 4,5-dihydro-4- methyl-5-(4-methylphenyl)-2-oxazolamine;
4-methyl-5- (4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine).
(23) 4-CMC; 4-Chloromethcathinone;
(24) Ethylphenidate;
(ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
(25) 4-Fluoroamphetamine;
1-(4-fluorophenyl)propan-2-amine; para -fluoroamphetamine;
D. Depressants:
Unless specifically exempt or unless listed in another schedule, any
material, compound, mixture or preparation which contains any quantity of the
following substances having a depressant effect on the central nervous system,
including its salts, isomers and salts of isomers whenever the existence of
such salts, isomers and salts of isomers is possible within the specific
chemical designation:
(1) Mecloqualone;
(2) Methaqualone; Quaalude;
(3) Benzodiazepines;
(a) Bromazepam;
(b) Camazepam;
(c) Cloxazolam;
(d) Delorazepam;
(e) Ethylloflazepate;
(f) Fludiazepam;
(g) Flunitrazepam;
Rohypnol;
(h) Haloxazolam;
(i) Ketazolam;
(j) Loprazolam;
(k) Lormetazepam;
(l) Medazepam;
(m) Nimetazepam;
(n) Nitrazepam;
(o) Nordiazepam;
(p) Oxazolam;
(q) Phenazepam
(r) Pinazepam;
(s) Tetrazepam;
(t) Flubromazepam;
(u) Diclazepam;
(v) Etizolam;
(w) Flualprazolam;
(x) Clonazolam;
(y) Flubromazolam;
(z) Bromazolam
(4) Gamma hydroxybutyric acid and
any chemical compound that is metabolically converted to GHB;
(5) Gamma butyrolactone and any chemical compound that is
metabolically converted to GHB;
(6) 1-4 butane diol and any chemical compound that is
metabolically converted to GHB
(7) GHV
or 4-methyl-GHB; γ-hydroxyvaleric acid;
(8) GVL; γ-valerolactone;
(9) MMQ; methylmethaqualone;
(10) MBQ; mebroqualone.
(11) 2-FDCK; 2-Fluorodeschloroketamine;
E. Hallucinogenic substances:
Unless specifically exempt or unless listed in another schedule, any
material, compound, mixture or preparation, which contains any quantity of the
following hallucinogenic substances, or which contains any of its salts,
isomers, and salts of isomers whenever the existence of such salts, isomers and
salts of isomers is possible within the specific chemical designation (for
purpose of this sub-section only, the term “isomers” includes the optical,
positional, and geometric isomers).
(1) MDA; 3,4[ ]-methylenedioxy[
]amphetamine;
(2) MMDA; 5[ ]-[ ]methoxy[
]- 3,4-methylenedioxy[ ]amphetamine;
(3) TMA; 3,4,5[ ]-trimethoxy[ ]amphetamine;
(4) Bufotenine;
(5) DET; (Diethyltryptamine);
(6) DMT; (Dimethyltryptamine);
(7) DOM or STP; (4-methyl-2,5-dimethoxy amphetamine);
[ (8) Lysergic acid amide;]
[(9)] (8) Lysergic acid diethylamide;
[(10)] (9) Mescaline;
[(11)] (10) Peyote;
[(12)] (11) N-ethyl-3-piperidyl
benzilate; JB 318;
[(13)] (12) N-methyl-3-piperidyl
benzilate; JB-336;
[(14)] (13) Psilocybin;
[(15)] (14) Psilocyn;
[(16)] (15) Parahexyl (synthetic analog of delta‑9‑tetrahydrocannabinol);
[(17)] (16) 2, 5
-dimethoxyamphetamine; 2, 5-DMA;
[(18)] (17) 4-bromo-2,
5-dimethoxy-amphetamine; 2, 5-DMA;
[(19)] (18) PMA;
4-methoxyamphetamine;
[(20)] (19) PCE;
(Eticyclidine[ Ethylamine]
N-ethyl-1-phenylcyclohexylamine);
[(21)] (20) Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy), (PHP) analog of the drug phencyclidine;
[(22)]
(21) Thiophene [(]analogs
of phencyclidine[)] (TCP,[ or] T[P]CPy or BTCP);
[(23)]
(22) Alpha-ethyltryptamine;
[(24)]
(23) 2,[ ]5-dimethoxy-4-ethylamphet[-]amine;
DOET;
[(25)]
(24) Ibogaine;
[(26)]
(25) 2C-T-7;
(2,5-dimethoxy-4-(n)-propylthiophenethylamine);
[(27)]
(26) AMT;
(Alpha-methyltryptamine);
[(28)]
(27) 5-MeO-DIPT;
(5-methoxy-N,N-diisopropyltryptamine);
[(29)]
(28) 25B-NBOMe;
(2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
[(30)]
(29) 25C-NBOMe;
(2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
[(31)]
(30) 25I-NBOMe;
(2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine).
[(32)]
(31) Synthetic
cannabinoids: Unless specifically
exempted or unless listed in another schedule, any material, compound, mixture or preparation which
contains any quantity of the following synthetic cannabinoids which
demonstrates binding activity to the cannabinoid receptor or analogs or
homologs with binding activity.
Substances include but are not limited to:
(a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl]
1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol);
(b) CP
55,940 (5-hydroxy-2-(3-hydroxypropyl)
cyclohexyl]-5-(2-methyloctan-2-yl)phenol);
(c) JWH-081
(1-pentyl-3-[1-(4-methoxynaphthoy)]indole);
(d) JWH-122
(1-pentyl-3-(4-methyl-1-naphthoyl)indole);
(e) JWH-133
3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H
dibenzo[b,d]pyran;
(f) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole);
(g) JWH
210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
(h) AM-694
(1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole);
(i) AM-1221
(1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole;
(j) AM-2201
(1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
(k) RCS-4
or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole);
(l) RCS-8
or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole);
(m) JWH-018[210]
(1-pentyl-3-(4-ethylnaphthoyl)indole);
(n) WIN-49,098
(Pravadoline)
(4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone;
(o) WIN-55,212-2
(2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6- yl)-1-naphthalenylmethanone);
(p) any
of the following synthetic cannabinoids, their salts, isomers, and salts of
isomers, unless specifically excepted, whenever the existence of these salts,
isomers, and salts of isomers is possible within the specific chemical
designation;
(i) naphthoylindoles: any compound containing a 3-(1- naphthoyl) indole structure with substitution at the
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or
not further substituted in the indole ring to any extent and whether or not
substituted in the naphthyl ring to any extent including, but not limited to,
JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398
and AM-2201;
(ii) naphthylmethylindoles:
any compound containing a1Hindol- 3-yl-(1-naphthyl) methane structure
with substitution at the nitrogen atom of the indole ring by an alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or
2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the naphthyl ring to any
extent including, but not limited to, JWH-175, JWH-184, and JWH-199;
(iii) naphthoylpyrroles:
any compound containing a 3-(1- naphthoyl)
pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by
an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or
2-(4-morpholinyl) ethyl group, whether or not further substituted in the
pyrrole ring to any extent and whether or not substituted in the naphthyl ring
to any extent including, but not limited to, JWH-307;
(iv) naphthylmethylindenes:
any compound containing a naphthylideneindene
structure with substitution at the 3-position of the indene ring by an alkyl,
haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or
not further substituted in the indene ring to any extent and whether or not
substituted in the naphthyl ring to any extent including, but not limited to,
JWH-176;
(v) phenylacetylindoles:
any compound containing a 3- phenylacetylindole
structure with substitution at the nitrogen atom of the indole ring by an
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or
2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the phenyl ring to any
extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8;
(vi) cyclohexylphenols:
any compound containing a 2-(3- hydroxycyclohexyl)
phenol structure with substitution at the 5- position of the phenolic ring by
an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or
2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl
ring to any extent including, but not limited to, Cannabicyclohexanol
(CP 47,497 C8 homologue), CP 47,497 and CP 55,490;
(vii) benzoylindoles: any
compound containing a 3-(benzoyl) [ 5 ] OTS-3833.4 indole structure with
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether
or not further substituted in the indole ring to any extent and whether or not
substituted in the phenyl ring to any extent including, but not limited to,
AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241;
(q) UR-144
1-(pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone;
(r) XLR11
1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone;
(s) APINACA or AKB48
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;
(t) QUPIC
or PB-22; Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;
(u) 5-fluoro-PB22; 5F-PB22; Quinolin-8-yl
1-(5-fluropentyl-1H-indole-3-carboxylate;
(v) AB-FUBINACA;
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-carboxamide;
(w) ADB-PINACA;
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;
(x) AB-CHMINACA;
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;
(y) AB-PINACA;
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;
(z) THJ-2201;
[1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone;
(aa) FDU-PB-22[ IUPAC]: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3
carboxylate;
(bb) 5-fluoro ABICA:
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;
(cc) FUB-144 or FUB-UR-144;
[1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(dd) MN-18; N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide;
(ee) FUB-PB-22 or QUFUBIC;
Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate;
[ (ff) ADB-CHMINACA
(N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);]
[(gg)] (ff) AMB-FUBINACA
or FUB-AMB or MMB-FUBINACA (methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
[(hh)] (gg) 5-fluoro-AMB
or 5F-AMB; (methyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) [
(N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester)];
[ (ii) 5-fluoro-ADB
(N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine, methyl
ester);]
[(jj)]
(hh) Bk-DMBDB
or dibutylone; 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one;
[ (kk) MMB-FUBINACA;
methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate;]
[(ll)]
(ii) MDMB-CHMICA or MMB-CHMINACA;
methyl
(S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
[(mm)] (jj) NM2201; Naphthalen-1-yl
1-(5-fluoropentyl)-1H-indole-3-carboxylate;
[(nn)] (kk) 5-Fluoro-AKB48 or
5F-APINACA;
N-((3s,5s,7s)-adamanta-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;
[(oo)] (ll) 5-Fluoro-ADB or 5F-ADB or 5F-MDMB-PINACA;
Methyl(S)-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate;
[ (pp) 5-Fluoro-AMB;
N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine,methyl ester;]
[(qq)] (mm) MAB-CHMINACA
or ADB-CHMINACA;
N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cycohexylmethyl)-1H-indazole-3-carboxamide;
[(rr)] (nn) SDB-006;
N-benzyl-1-pentyl-1H-indole-3-carboxamide;
[(ss)] (oo) Cumyl-PINACA
or SGT-24; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide;
[(tt)] (pp) Cumyl-PICA
or SGT-56; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide;
[(uu)] (qq) 5F-CUMYL-PINACA; SGT-25; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-
yl)-1H-indazole-3-carboxamide;
[(vv)] (rr) 5F-EDMB-PINACA; Ethyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate;
[ (ww) methyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB;
5F-MDMB-PINACA];]
[(xx)] (ss) N
-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide
(FUB-AKB48; FUB-APINACA; AKB48 N -(4-fluorobenzyl));
[(yy)] (tt) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide
(4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA,
CUMYL-4CN-BINACA, or SGT-78);
[(zz)] (uu) methyl 2-(1-(cyclohexylmethyl)-1
H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA or AMB-CHMICA);
[(aaa)] (vv) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
H-pyrrolo[2,3-b]pyridine-3-carboxamide (5F-CUMYL-P7AICA)
(ww) 4F-MDMB-BUTICA;
(methyl 2-[[1-(4-fluorobutyl) indole-3-carbonyl]
amino]-3,3-dimethyl-butanoate);
(xx) 5F-EDMB-PICA; (ethyl
2-[[1-5-fluoropentyl) indole-3- carbonyl] amino-3,3-dimethyl-butanoate;
(yy) 5F-MDMB-PICA;
Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
(zz) ADB-4EN-PINACA;
(N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide;
(aaa) CUMYL-PEGACLONE;
SGT-151 (5-pentyl-2-(2-phenylpropan-2- yl)
pyrido[4,3-B] indole-1-one;
(bbb) MDMB-4EN-PINACA;
(methyl 3,3-dimethyl-2-(1-(pent-4- en-1-yl)-1H-indazole-3-carboxamido)
butanoate);
(ccc) MMB-FUBICA; (methyl
2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methyl butanoate;
(ddd) ADB-BUTINACA;
(N-(1-amino-3,3-dimethyl-1-oxobutan-2- yl)-1-butyl-1H-indazole-3-carboxamide);
(eee) 4F-MDMB-BINACA; 4F-MDMB-BUTINACA or
methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3¬dimethylbutanoate);
(fff) 5F-AB-PINACA;
(N-(1-amino-3-methyl-1-oxobutan-2- yl)-1-(5-fluoropentyl)-1
H-indazole-3-carboxamide);
(ggg) ADB-FUBINACA; (N-(1-amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3- carboxamide);
(hhh) MDMB–FUBINACA; (methyl
2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3,3-dimethylbutanoate);
[(33)] (32) Substances
determined by the board to have the pharmacological effect of the substance,
the risk to the public health by abuse of the substance and the potential of
the substance to produce psychic or physiological dependence liability is
similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA
1978. Substances include but are not
limited to:
(a) Salvia
divinorum;
(b) Salvinorin A (methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate);
[(34)] (33) (4-MEC); 4-methyl-ethylcathinone;
[(35)]
(34) (4-EMC); 4-ethyl-methcathinone;
[(36)]
(35) Ethcathinone;
2-ethylamino-1-phenyl-propan-1-one;
[(37)]
(36) Ethylone; 3’,4’-methylenedioxy-N-ethylcathinone;
[(38)]
(37) Bk-MBDB,
butylone; beta-keto-N-methyl-3,4-benzodioxyolybutanamine;
[(39)]
(38) (NRG-1), naphyrone;
naphthylpyrovalerone;
[(40)]
(39) Metamfepramone;
N,N-dimethylcathinone;
[(41)]
(40) Alpha-PPP;
alpha-pyrrolidinopropiophenone;
[(42)]
(41) (α-PBP); alpha-pyrrolidinobutiophenone;
[(43)]
(42) (MOPPP);
4’-methoxy-alpha-pyrrolidinopropiophenone;
[(44)]
(43) (MαPPP); 4’-methyl-α-pyrrolidinopropiophenone;
[(45)]
(44) (MDPPP);
3’,4’-methylenedioxy-alpha-pyrrolidinopropiophenone;
[(46)]
(45) (MDPBP);
3’,4’-methylenedioxy-alpha-pyrrolidinobutiophenone;
[(47)]
(46) (MPBP);
4’-methyl-α-pyrrolidinobutiophenone;
[(48)]
(47) Alpha-PVP;
alpha-pyrrolidinovalerophenone;
[(49)]
(48) (MDAI);
5,6-methylenedioxy-2-aminoindane;
[(50)]
(49) Buphedrone; alpha-methylamino-butyrophenone;
[(51)]
(50) Eutylone; beta-keto-ethylbenzodioxolylbutanamine;
[(52)]
(51) beta-keto-ethylbenzodioxolylpentanamine; (N-Ethylpentylone
or Ephylone);
[(53)]
(52) beta-keto-methylbenzodioxolylpentanamine (pentylone);
[(54)]
(53) 4-Bromo-2,5-dimethoxyphenethylamine
(2c-B, Nexus);
[(55)]
(54) N-hydroxy-3,4-methylenedioxyamphetamine
(also known as N-hydroxy-alphamethyl-3,4(methylenedioxy)-phenethylamine, and
N-hydroxy MDA;
[(56)]
(55) 5-methoxy-N,N-dimethyltryptamine
(5-methoxy-3-[2-(dimethylamino)ethyl]indole;
5-MeO-DMT;
[(57)]
(56) Mephedrone
or 4-MMC; 4-methylmethcathinone;
[(58)]
(57) (MDPV);
3,4-methylenedioxypyrovalerone;
[(59)]
(58) (2C-E)
or aquarust; 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;
[(60)]
(59) (2C-D);
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;
[(61)]
(60) (2C-T-2);
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine;
[(62)]
(61) (2C-T4);
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine;
[(63)]
(62) (2C-H);
2-(2,5-Dimethoxyphenyl)ethanamine;
[(64)]
(63) (2C-N);
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;
[(65)]
(64) (2C-P);
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;
[(66)]
(65) Methylone;
3,4-Methylenedioxy-N-methylcathinone;
[(67)]
(66) Aminorex
(2-amino-5-phenyl-2-oxazoline);
[(68)]
(67) Pentedrone;
[(69)]
(68) 4-FMC
or flephedrone; 4-fluro-N-methylcathinone;
[(70)]
(69) (3-FMC);
3-fluro-N-methylcathinone;
[(71)]
(70) (3-MMC);
3-methylmethcathinone;
[(72)]
(71) (3,4
DMMC); 3,4-Dimethylmethcathinone;
[(73)]
(72) (3-MEC);
3-Methyl-N-ethylcathinone;
[(74)]
(73) 4-methylbuphedrone
or 4-MeBP; 2-methylamino-1-(4-methylphenyl)butan-1-one
[(75)]
(74) (4
MTA); 4-methylthioamphetamine;
[(76)]
(75) (5-Me
MDA); 5-methyl-3,4-methylenedioxyamphetamine;
[(77)]
(76) (6-APB);
6-benzofuran;
[ (78) (PMA); 4-methoxyamphetamine;
(79) (2C-B);
2,5-dimethoxy-4-bromophenethylamine;]
[(80)] (77) (2C-C);
2,5-dimethoxy-4-chlorophenethylamine;
[ (81) (2C-D);
4-methyl-2,5-dimethoxyphenethylamine;
(82) (2C-E, aquarust,
cindy); 2,5-dimethoxy-4-ethylphenethylamine;]
[(83)] (78) (2C-G);
3,4-dimethyl-2,5-dimethoxyphenethylamine;
[(84)] (79) (2C-I);
2,5-dimethoxy-4-iodophenethylamine;
[(85)] (80) (2C-T21);
2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl]ethanamine;
[(86)] (81) (2C-B-FLY);
2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine;
[(87)] (82) Bromo-DragonFLY
or 3C-Bromo-Dragonfly or DOB-Dragonfly;
1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine;
[(88)] (83) (DOB);
2,5-Dimethoxy-4-bromoamphetamine;
[(89)] (84) (DOC);
2,5-Dimethoxy-4-chloroamphetamine;
[ (90) (DOM);
2,5-Dimethoxy-4-methylamphetamine;]
[(91)] (85) (TMA2);
2,4,5-trimethoxyamphetamine;
[(92)] (86) (TMA6);
2,4,6-trimethoxyamphetamine;
[(93)] (87) (MDAT);
6,7-methylenedioxy-2-aminotetralin;
[(94)] (88) (4-acetoxy DiPT,
ipracetin); 4-acetoxy-N,N-diisopropyltryptamine;
[(95)] (89) (4-acetoxy
DMT, psilacetin;) O-Acetylpsilocin;
[(96)] (90) 4-HO MET, metocin;
4-hydroxy-N-methyl-N-ethyltryptamine;
[(97)] (91) 4-HO MiPT, hats;
4-hydroxy-N-methyl-N-isopropyltryptamine;
[(98)] (92) 5-MeO-aMT, Alpha-O; 5-methoxy-α-methyltryptamine;
[(99)] (93) (5-MeO-MiPT);
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine;
[(100)] (94) (DiPT);
N,N-diisopropyltryptamine;
[(101)] (95) (DPT); dipropyltryptamine;
[(102)] (96) (5-MeO-DALT);
N,N-diallyl-5-methoxytryptamine;
[(103)] (97) (3-MeO PCP); 3-methoxyphencyclidine;
[(104)] (98) (4-MeO PCP); 4-methoxyphencyclidine;
[(105)] (99) (MK-801); dizocilpine;
[ (106) (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;
(107) (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;]
[(108)] (100) (PCPr); phencyclamine,
N-(1-phenylcyclohexyl)propanamine;
[(109)] (101) [(] Tenocyclidine or TCP [)];
1-(1-(2-thienyl)cyclohexyl)piperidine
[(110)] (102) (3-MeO PCE); 3-methoxyeticyclidine,
N-ethyl-1-(3-methoxyphenyl)cyclohexanamine;
[(111)] (103) (ETH-LAD); 6-ethyl-6-nor-lysergic acid
diethylamide;
[(112] (104) (AL-LAD); 6-allyl-6-nor-LSD;
[(113)] (105) (PRO-LAD);
10-didehydroergoline-8-carboxamide;
[ (114) ((1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one, N- ethylpentylone);]
[(115)] (106) (MPHP),
4´-methyl-alpha-pyrrolidinohexiophenone;
[(116)] (107) 4'-chloro-alpha-pyrrolidinovalerophenone
(4-chloro-α-PVP; 4'-chloro-α-pyrrolidinopentiophenone);
[(117)] (108) 4-methyl-alpha-ethylaminopentiophenone
(4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);
[(118)] (109) Alpha-pyrrolidinoheptaphenone
(PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
[(119)] (110) Alpha-pyrrolidinohexanophenone
(α-PHP; α-pyrrolidinohexanophenone;
1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
[(120)] (111) N-ethylhexedrone
(α-ethylaminohexanophenone; 2-(ethylamino)-1- phenylhexan-1-one);
[(121)] (112) Methoxetamine; 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one; 2-(3-methoxyphenyl)-2-(N-ethylamino)cyclohexanone;
MXE).
(113) 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine; TCPy;
(114) Alpha- Pyrrolidinoisohexanophenone
or α-PHiP or A-PiHP;
(4-methyl-1-phenyl-2-(pyrrolidin-1- YL) pentan-1 one);
(115) MDEA;
3,4-Methylenedioxy-N-ethylamphetamine;
(116) MePPP;
4-methyl-α-pyrrolidinopropiophenone; 1-(4-
methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one;
(117) Dipentylone;
1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one;
F. Any material, compound, mixture or preparation which
contains any quantity of the following substances.
(1) 3, 4-methylenedioxymethamphetamine (MDMA), its optical,
positional and geometric isomers, salts and salts of isomers;
(2) (MPPP); 1-methyl-4-phenyl-4-proprionoxypiperidine its
optical isomers, salts, and salts of isomers;
(3) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP),
its optical isomers, salts and salts of isomers;
(4) Cathinone;
(5) Methcathinone;
(6) Tianeptine;
(7) Para- Methoxymethamphetamine (PMMA)
[16.19.20.65
NMAC - Rp 16.19.20.65 NMAC, 6/26/2018; A, 12/17/2019; A, 9/14/2021; A, 6/13/2023; A, 11/17/2026]
16.19.20.66 SCHEDULE II:
A. Opioids: Unless specifically excepted or unless in
another schedule any of the following opioids, including its isomers, esters,
ethers, salts and salts of isomers, esters, and ethers whenever the existence
of such isomers, esters, ethers, and salts is possible within the specific
chemical designation except dextro and
levopropoxyphene.
(1) Alphaprodine;
(2) Anileridine;
(3) Bezitramide;
(4) Diphenoxylate;
(5) Dihydrocodeine;
(6) Dextropropoxyphene
(bulk) non-dosage form;
(7) Fentanyl;
(8) Isomethadone;
(9) Levomethorphan;
(10) Levorphanol;
(11) Metazocine;
(12) Methadone;
(13) Methadone intermediate; 4-cyano-2-dimethylamino-4,
4-diphenylbutane;
(14) Moramide-Intermediate,
2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid;
(15) Pethidine; or Meperidine or Demerol;
(16) Pethidine intermediate A; 4-cyano-1-methyl-4-phenylpiperidine;
(17) Pethidine intermediate B or
Norpethidine; ethyl-4-phenyl-piperdine-4-carboxylate;
(18) Pethidine intermediate C or Pethidinic acid; 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(19) Phenazocine;
(20) Piminodine;
(21) Racemethorphan;
(22) Racemorphan;
(23) Sufentanil;
(24) Carfentanil;
(25) (LAAM); Levo-alphacetylmethadol;
(26) Tapentadol;
(27) Thiafentanil;
(28) Norfentanyl;
(29) Oliceridine.
(30) ANPP; despropionyl
fentanyl;
(31) Noroxymorphone;
B. Shall
consist of the drugs and other substances, by whatever official name, common or
usual name, chemical name or brand name designated, listed in this
section. Substance, vegetable origin or
chemical synthesis. Unless specifically
exempt or unless listed in another schedule, any of the following substances
whether produced directly or indirectly by extraction from substances of
vegetable origin, or independently by means of chemical synthesis, or by a
combination of extraction and chemical synthesis.
(1) Opium
and opiate, and any salts, compound, derivative, or preparation of opium or
opiate excluding naloxone, dextrorphan, nalbuphine,
naltrexone and apomorphine but including the following:
(a) Raw opium;
(b) Opium extracts;
(c) Opium fluid extracts;
(d) Powdered opium;
(e) Granulated opium;
(f) Tincture of opium;
(g) Codeine;
(h) Ethylmorphine;
(i) Etorphine hydrochloride;
(j) Hydrocodone;
(k) Hydromorphone;
(l) Metopon;
(m) Morphine;
(n) Oxycodone;
(o) Oxymorphone;
(p) Thebaine;
(q) Alfentanil;
(r) Oripavine.
(2) Any salt, compound derivative, or preparation thereof, which
is chemically equivalent or identical with any of the substances referred to in
Paragraph (1) of Subsection A of 16.19.20.66 NMAC, except that these substances
shall not include the isoquinoline alkaloids of
opium.
(3) Opium poppy and poppy straw.
(4) Coca leaves and any salt, compound, derivative or
preparation of coca leaves and any salt, compound, derivative or preparation
thereof which is chemically equivalent or identical with any of these
substances, except that the substances shall not include de-cocainized coca
leaves or extraction of coca leaves, which extractions do not contain cocaine
or ecgonine.
C. Stimulants: Unless specifically exempt or unless listed in another
schedule, any material, compound, mixture or preparation which contains any
quantity of the following substances having a stimulant effect on the central
nervous system. (See 16.19.21 NMAC- Drug
Precursors)
(1) Amphetamine, its salts, optical isomers and salts of its
optical isomers.
(2) Methamphetamine, its salts, isomers and salts of isomers.
(3) Phenmetrazine and its salts.
(4) Methylphenidate.
(5) Lisdexamfetamine.
D. Depressants: Unless specifically exempt or unless listed
in another schedule any material, compound mixture or preparation which
contains any quantity of the substance having a depressant effect on the
central nervous system, including its salts, isomers and salts of isomers is
possible within the specific chemical designation.
(1) Amobarbital;
(2) Secobarbital;
(3) Pentobarbital;
(4) Phencyclidine;
(5) Glutethimide;
(6) 1-phenylcyclohexylamine;
(7) 1-piperidinocyclohexanecarbonitrile;
(8) Dronabinol in an oral solution in a drug product approved
for marketing by the U.S. Food and Drug Administration.
E. Hallucinogenic substances:
Unless specifically exempt or unless listed in another schedule, any
material, compound, mixture or preparation, which contains any quantity of the
following hallucinogenic substances, or which contains any of its salts,
isomers and salts of isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation (for
purpose of this paragraph only, the term “isomers” includes the optical,
positional, and geometric isomers):
(1) Nabilone;
(2) Phenylacetone
(P2P, benzyl methyl ketone; methyl benzyl ketone).
F. Miscellaneous:
(1) Dihydroetorphine;
(2) Bulk dextropropoxyphene;
(3) Remifentanil.
[16.19.20.66
NMAC - Rp 16.19.20.66 NMAC, 6/26/2018; A, 12/17/2019; A, 6/13/2023; A, 11/17/2026]
16.19.20.67 SCHEDULE III: Shall consist of drugs and other substances, by whatever
official name, common or usual name designated listed in this section.
A. Narcotic
drugs: Unless specifically exempt or
unless listed in another schedule, any material, compound, mixture or
preparation containing limited quantities of the following narcotic drugs, or
any salts thereof.
(1) Not more than one and eight-tenths grams of codeine per 100
milliliters or not more than 90 milligrams per dosage unit, with an equal or
greater quantity of an isoquinoline alkaloid of
opium.
(2) Not more than one and eight-tenths grams of codeine per 100
milliliters or not more than 90 milligrams per dosage units, with one or more
active nonnarcotic ingredients in recognized therapeutic amounts.
(3) Not more than 300 milligrams of dihydrocodeinone per 100
milliliters or not more than 15 milligrams per dosage unit, with a fourfold or
greater quantity of an isoquinoline alkaloid of
opium.
(4) Not more than 300 milligrams of dihydrocodeinone per 100
milliliters or not more than 15 milligrams per dosage unit, with one or more
active, nonnarcotic ingredients in recognized therapeutic amounts.
(5) Not more than one and eight-tenths grams of dihydrocodeine
per 100 milliliters or not more than 90 milligrams per dosage unit, with one or
more active, nonnarcotic ingredients in recognized therapeutic amounts.
(6) Not more than 300 milligrams of ethylmorphine
per 100 milliliters or not more than 15 milligrams per dosage unit, with one or
more active, nonnarcotic ingredients in recognized therapeutic amounts.
(7) Not more than 500 milligrams of opium per 100 milliliters or
per 100 grams or not more than 25 milligrams per dosage unit, with one or more
active, nonnarcotic ingredients in recognized therapeutic amounts.
(8) Not more than 50 milligrams of morphine per 100 milliliters
or per 100 grams, with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts.
B. Stimulants: Unless specifically exempt or unless listed
in another schedule, any material, compound, mixture or preparation which
contains any quantity of the following substances having a stimulant effect on
the central nervous system.
(1) Those compounds, mixtures or preparations in dosage unit
form containing any stimulant, amphetamine, phenmetrazine or methamphetamine
previously exempt, for which the exemption was revoked by FDA Regulation Title
21, Part 308.13, and any other drug of the quantitative composition shown in
that regulation for those drugs or which is the same except that it contains a
lesser quantity of controlled substances.
(2) Benzphetamine;
(3) Phendimetrazine;
(4) Chlorphentermine;
(5) Clortermine.
C. Depressants: Unless specifically exempt or unless listed
in another schedule, any material, compound, mixture or preparation which
contains any quantity of the following substances having a depressant effect on
the central nervous system.
(1) Any compound, mixture or preparation containing:
(a) Amobarbital;
(b) Secobarbital;
(c) Pentobarbital;
(d) Butalbital; or any salt thereof and one or more active
medicinal ingredients which are not listed in any schedule.
(2) Any suppository dosage form containing:
(a) Amobarbital;
(b) Secobarbital;
(c) Pentobarbital; or any salt of any of these drugs approved by
the FDA for marketing only as a suppository.
(3) Any substance which contains any quantity of a derivative of
barbituric acid or any salt of a derivative of barbituric acid.
(4) Chlorhexadol;
(5) Lysergic Acid;
(6) Lysergic Acid Amide;
(7) Methyprylon;
(8) Sulfondiethylmethane;
(9) Sulfonethylmethane;
(10) Sulfonmethane;
(11) Telazol; Tiletamine/zolazepam;
(12) Ketamine Hydrochloride.
(13) Any
drug product containing gamma hydroxybutyric acid, including its salts,
isomers, and salts of isomers, for which an application is approved under
Section 505 of the Federal Food, Drug and Cosmetic Act.
(14) Embutramide;
(15) Dronabinol
(synthetic) in sesame oil and encapsulated in soft gelatin capsules in a drug
product approved by the U.S. food and drug administration.
(16) Perampanel.
D. Miscellaneous:
(1) Nalorphine (a narcotic drug);
(2) Buprenorphine;
(3) Clenbuterol.
E. Anabolic
steroids: The term “anabolic
steroid” means any drug or hormonal substance, chemically and pharmacologically
related to testosterone (other than estrogens, progestins, [and]
corticosteroids, and dehydroepiandrosterone) [ that promotes muscle
growth] includes
(but is not limited to) the substances listed below
The
drug or substance has been created or manufactured with the intent of producing
a drug or other substance that either;
(1) Promotes muscle growth; or
(2) Otherwise causes a pharmacological effect similar to that of
testosterone; or
(3) The drug or substance has been, or is intended to be,
marketed or otherwise promoted in any manner suggesting that consuming it will
promote muscle growth or any other pharmacological effect similar to that of
testosterone. Unless specifically exempt or unless listed
in another schedule, any material, compound, mixture or preparation which
contains any quantity including
its salts, esters and ethers
of the following substances listed in this section:
(1) Androstanedione;
5α-Androstan-3,17-dione;
(2) Kneller’s Trione;
5α-Androstan-3,6,17-trione;
(3) 1-Androstenediol
(3β,17β-dihydroxy-5α-androst-1-ene);
(4) 1-Androstenediol
(3α,17β-dihydroxy-5α-androst-1-ene);
(5) 4-Androstenediol
(3β,17β-dihydroxy-androst-4-ene);
(6) 5-Androstenediol
(3β,17β-dihydroxy-androst-5-ene);
(7) 1-Androstenedione (5α-androst-1-en-3,17-dione);
(8) 4-Androstenedione
(androst-4-en-3,17-dione);
(9) 5-Androstenedione
(androst-5-en-3,17-dione);
(10) Bolasterone;
(7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
[(1)] (11) Boldenone;
(17β-hydroxyandrost-1,4-diene-3-one);
(12) Boldione;
(androsta-1,4-diene-3,17-dione);
(13) 6-Bromo-androsta-1,4-diene-3,17-dione;
(14) 6-Bromo-androstan-3,17-dione;
[(2)] (15) [Chloro testosterone;]
Calusterone; (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
(16) 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;
(17) Chloromethylandrostenediol;
4-Chloro-17α-methyl-androst-4-ene-3β,17β-diol;
(18) 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;
(19) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;
[(3)] (20) Clostebol
or 4-Chlorotestosterone;
[PD140.1](4-chloro-17β-hydroxyandrost-4-en-3-one);
[(4)] (21) Dehydrochlormethyltestosterone
or Oral Turinabol;
(4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one);
(22) Desoxymethyltestosterone
or Madol;
(17α-methyl-5α-androst-2-en-17β-ol);
[(5)] (23) [Dihydrotestosterone]
4-dihydrotestosterone; (17β-hydroxy-androstan-3-one);
(24) Δ1-dihydrotestosterone or
1-testosterone; (17β-hydroxy-5α-androst-1-en-3-one);
(25) 3β,17β-dihydroxy-5α-androstane;
(26) 3α,17β-dihydroxy-5α-androstane;
(27) 2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;
[(6)] (28) Drostanolone;
(17β-hydroxy-2α-methyl-5α-androstan-3-one);
(29) Methylepitiostanol;
2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;
(30) Trendione;
estra-4,9,11-triene-3,17-dione;
(31) 13β-ethyl-17β-hydroxygon-4-en-3-one;
[(7)] (32) Ethylestrenol;
(17α-ethyl-17β-hydroxyestr-4-ene);
[(8)] (33) Fluoxymesterone;
(9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one;
[(9)] (34) Formebolone;
(2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one);
(35) Furazabol; (17α-methyl-17β-hydroxyandrostano[2,3-c]furazan);
(36) [3,2-c]furazan-5α-androstan-17β-ol;
(37) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
(38) 4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one);
(39) 4-hydroxy-androst-4-ene-3,17-dione;
(40) 17β-hydroxy-androstano[2,3-d]isoxazole;
(41) 17β-hydroxy-androstano[3,2-c]isoxazole;
(42) 3β-hydroxy-estra-4,9,11-trien-17-one;
(43) 4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one);
[(10)]
(44) Mestanolone;
(17α-methyl-17β-hydroxy-5α-androstan-3-one);
[(11)] (45) Mesterolone;
(17α-methyl-17β-hydroxy-5α-androstan-3-one);
[(12)] (46) Methandienone or Methandrostenolone;
(17α-methyl-17β-hydroxyandrost-1,4-dien-3-one);
[ (13) Methandranone;]
[(14)] (47) Methandriol
(17α-methyl-3β,17β-dihydroxyandrost-5-ene);
[ (15) Methandrostenolone;]
(48) Methasterone;
(2α,17α-dimethyl-5α-androstan-17β-ol-3-one or
2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one);
[(16)] (49) Methenolone;
(1-methyl-17β-hydroxy-5α-androst-1-en-3-one);
(50) 17α-methyl-androsta-1,4-diene-3,17β-diol;
(51) 17α-methyl-5α-androstan-17β-ol;
(52) 17α-methyl-androstan-3-hydroxyimine-17β-ol;
(53) 6α-methyl-androst-4-ene-3,17-dione;
(54) 17α-methyl-androst-2-ene-3,17β-diol;
(55) 17α-methyl-3β,17β-dihydroxy-5α-androstane;
(56) 17α-methyl-3α,17β-dihydroxy-5α-androstane;
(57) 17α-methyl-3β,17β-dihydroxyandrost-4-ene;
(58) 17α-methyl-4-hydroxynandrolone
(17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one);
(59) Methyldienolone;
(17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);
(60) 17α-methyl-Δ1-dihydrotestosterone
(17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (a.k.a.
“17-α-methyl-1-testosterone”);
[(17)]
(61) Methyltrienolone;
(17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one);
[(18)] (62) Methyltestosterone;
(17α-methyl-17β-hydroxyandrost-4-en-3-one);
[(19)] (63) Mibolerone;
(7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one);
[(20)] (64) Nandrolone; (17β-hydroxyestr-4-en-3-one);
(65) 19-nor-4-androstenediol
(3β,17β-dihydroxyestr-4-ene);
(66) 19-nor-4-androstenediol
(3α,17β-dihydroxyestr-4-ene);
(67) 19-nor-5-androstenediol
(3β,17β-dihydroxyestr-5-ene);
(68) 19-nor-5-androstenediol
(3α,17β-dihydroxyestr-5-ene);
(69) 19-nor-4,9(10)-androstadienedione
(estra-4,9(10)-diene-3,17-dione);
(70) 19-nor-4-androstenedione
(estr-4-en-3,17-dione);
(71) 19-nor-5-androstenedione
(estr-5-en-3,17-dione);
[(21)]
(72) Norbolethone;
(13β,17α-diethyl-17β-hydroxygon-4-en-3-one);
(73) Norclostebol;
(4-chloro-17β-hydroxyestr-4-en-3-one);
[(22)] (74) Norethandrolone; (17α-ethyl-17β-hydroxyestr-4-en-3-one);
(75) Normethandrolone;
(17α-methyl-17β-hydroxyestr-4-en-3-one);
[(23)] (76) Oxandrolone; (17α-methyl-17β-hydroxy-2-oxa-5α-androstan-3-one);
[(24)] (77) Oxymesterone; (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one);
[(25)] (78) Oxymetholone; (17α-methyl-2-hydroxymethylene-17β-hydroxy-5α-androstan-3-one);
(79) Prostanozol;
(17β-hydroxy-5α-androstano[3,2-c]pyrazole or [3,2-c]pyrazole-5α-androstan-17β-ol);
(80) [3,2-c]pyrazole-androst-4-en-17β-ol;
[(26)] (81) Stanolone or Dihydrotestosterone;
5α-androstan-17β-ol-3-one;
[(27)] (82) Stanozolol; (17α-methyl-17β-hydroxy-5α-androst-2-eno[3,2-c]-pyrazole);
(83) Stenbolone
(17β-hydroxy-2-methyl-5α-androst-1-en-3-one);
[(28)] (84) Testolactone(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
acid lactone);
[(29)] (85) Testosterone; (17β-hydroxyandrost-4-en-3-one);Tetrahydrogestrinone;
(13β,17α-diethyl-17β-hydroxygon-4,9,11-trien-3-one);
[(30)] (86) Trenbolone(17β-hydroxyestr-4,9,11-trien-3-one);[
and]
[(31)] (87) and
any salt, ester, or isomer of a drug or substance described or listed in
this paragraph, if that salt, ester, or
isomer promotes muscle growth.
F. Exempt
anabolic steroids: Compounds, mixtures,
or preparations that contain an anabolic steroid that have been exempted by the
board from Subsection E of 16.19.20.67 NMAC, schedule III to the same extent
that the substance has been exempted from the application of the Federal
Controlled Substance Act, if the substance is listed as an exempt anabolic
steroid product under 21 C.F.R. Section 1308.34 and its subsequent amendments.
[16.19.20.67
NMAC - Rp 16.19.20.67 NMAC, 6/26/2018; A, 11/17/2026]
16.19.20.68 SCHEDULE IV: Shall consist of the drugs and other substances, by whatever
official name, common or usual name, chemical name, or brand name designated,
listed in this section.
A. Depressants: Unless specifically exempt or unless listed
in another schedule, any material, compound, mixture or preparation which
contains any quantity of the following substances, including its salts,
isomers, and salts of isomers whenever the existence of such salts, isomers and
salts of isomers is possible within the specific chemical designation:
(1) Alfaxalone;
(2) Alprazolam;
(3) Barbital;
(4) Chloral Betaine;
(5) Chloral Hydrate;
(6) Chlordiazepoxide;
(7) Clobazam;
(8) Clonazepam;
(9) Clorazepate;
(10) Clotiazepam
(11) Diazepam;
(12) Estazolam;
(13) Ethchlorvynol;
(14) Ethinamate;
(15) Flurazepam;
(16) Fospropofol;
(17) Halazepam;
(18) Lorazepam;
(19) Mebutamate;
(20) Meprobamate;
(21) Methohexital;
(22) Methylphenobarbital;
(23) Midazolam;
(24) Oxazepam;
(25) Paraldehyde;
(26) Petrichloral;
(27) Phenobarbital;
(28) Prazepam;
(29) Quazepam;
(30) Remimazolam;
(31) Suvorexant;
(32) Temazepam;
(33) Triazolam;
(34) Brexanolone.
B. Lorcaserin:
Any material, compound, mixture or preparation which contains any
quantity of the following substance, including its salts, isomers (whether
optical, positional, or geometric) and its salts, or such isomers, whenever the
existence of such salts, isomers, and salts of isomers is possible: Lorcaserin.
C. Stimulants: Unless
specifically exempt or unless listed in another schedule any material,
compound, mixture or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system, including
its salts, isomers (whether optical, positional, or geometric) and salts of
such isomers whenever the existence of such salts, isomers and salts of isomers
is possible within the specific chemical designation:
(1) Diethylpropion;
(2) Phentermine;
(3) Pemoline (including organometallic complexes and chelates
thereon);
(4) Pipradrol;
(5) SPA ((-)-1-dimethyl amino-1,2-diphenylmethane);
(6) Mazindol;
(7) Cathine;
(8) Fencamfamin;
(9) Fenproporex;
(10) Mefenorex;
(11) Modafinil;
(12) Sibutramine;
(13) Solriamfetol;
(14) Serdexmethylphenidate.
D. Other
substances: Unless specifically
exempt or unless listed in another schedule, any material, compound, mixture or
preparation which contains any quantity of the following substances, including
its salts:
(1) Dextropropoxyphene(Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);
(2) Pentazocine;
(3) Carisoprodol;
(4) Nalbuphine Hydrochloride;
(5) Butorphanol Tartrate;
(6) Dezocine;
(7) Dichloralphenazone;
(8) Zaleplon;
(9) Zolpidem;
(10) Eszopiclone;
(11) Tramadol;
(12) Eluxadoline
(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
acid) (including its optical isomers) and its salts, isomers, and salts of
isomers
(13) Lemborexant;
(14) Daridorexant
(15) Zuranolone;
E. Narcotic
drug: Unless specifically exempt or
unless listed in another schedule, any material, compound, mixture or
preparation containing limited quantities of any of the following narcotic
drugs or any salts thereof: Not more
than one milligram of difenoxin and not less than 25
micrograms of atropine sulfate per dosage unit.
F. Exemption
of chloral: When packaged in a
sealed, oxygen-free environment, under nitrogen pressure, safeguarded against
exposure to the air. Chloral when
existing under the above conditions is a substance which is not intended for
general administration to a human being or another animal, and contains no
narcotic controlled substances and is packaged in such a form that the package
quantity does not present any significant potential for abuse. All persons who engage in industrial
activities with respect to such chloral are subject to registration; but shall
be exempt from Section 30-31-16 through 19 of the New Mexico Controlled
Substances Act and 16.19.20.19 NMAC through 16.19.20.52 NMAC of the board of
pharmacy regulations.
G. Exempt
compounds: Librax
and Menrium are preparations which contain
chlordiazepoxide, a depressant listed in schedule IV, Paragraph (6) of
Subsection A of 16.19.20.68 NMAC and other ingredients in such combinations,
quantity, preparation or concentration as to vitiate the potential for abuse of
chlordiazepoxide, and are hereby exempt preparations.
(1) Librax;
(2) Menrium, 5-2;
(3) Menrium, 4-5;
(4) Menrium, 10-4.
[16.19.20.68
NMAC - Rp 16.19.20.68 NMAC, 6/26/2018; A, 9/14/2021; A, 6/13/2023; A, 11/17/2026]